Derived from the metastatic tumor of a gastric cancer found
in the liver of a human patient, NCI-N87 cells are known for their distinct
expression of several factors; testing positive for ERBB2, myc, and other
oncogenes, NCI-N87 cells are useful tools for research into lung cancer
expression pathways. Cost-efficient therapy testing involving the cells can use
pre-optimized transfection
reagents to ensure realistic results that can translate to in vivo trials in human patients.
Currently, there is a necessity for cheap drugs against lung cancer, which is
one of the most prevalent cancers in non-developed countries. With more
research and gene therapy development, accessible solutions can be found, with
broader implications for the treatment of other variations of lung cancer.
The NCI-N87 epithelial cell line was originally established from the stomach tissue of a male patient with gastric carcinoma. They are extracted from the metastatic site located in the liver. The NCI-N87 cells test positive for myc and ERRBB2 oncogenes, express carcinoembryonic antigen (CEA), receptors for muscarinic cholinergic agents and TAG 72 surface glycoproteins. Transfection Reagent for NCI-N87 Cells (Gastric Carcinoma Cells, CRL-5822)
Comments
Post a Comment